Search results
Results from the WOW.Com Content Network
Instead, the drugs affect new blood cells that are being made by the bone marrow. [4] When myelosuppression is severe, it is called myeloablation. [5] Many other drugs including common antibiotics may cause bone marrow suppression. Unlike chemotherapy the effects may not be due to direct destruction of stem cells but the results may be equally ...
Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or hyperthermia therapy. Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved ...
Myelosuppression, neurotoxicity and paralytic ileus. Vinflunine: IV: As above. Bladder cancer: As per vinblastine. Vinorelbine: IV: As above. Breast cancer and non-small cell lung cancer. As above. 1.09 Alkylating agents: Altretamine: PO Alkylates DNA. Recurrent or advanced ovarian cancer Myelosuppression, peripheral neuropathy, seizures and ...
The nadir of this myelosuppression usually occurs 21–28 days after the first treatment, after which the blood cell and platelet levels in the blood begin to stabilize, often coming close to its pre-carboplatin levels. This decrease in white blood cells (neutropenia) can cause complications, and is sometimes treated with drugs like filgrastim.
Anthracycline administration is often accompanied by adverse drug reactions that limit the use of anthracyclines in the clinics. Two major dose limiting toxicities of anthracyclines include myelosuppression and cardiotoxicity. Fortunately, the introduction of therapeutic cytokines allows management of myelosuppression.
One drug has been FDA approved for mediating chemotherapy-induced side effects. Trilaciclib (V03AF12, trade name Cosela) was approved in February 2021 to reduce chemotherapy-induced myelosuppression in patients with late-stage small-cell lung cancer (ES-SCLC). [20]
Vincristine is delivered via intravenous infusion for use in various types of chemotherapy regimens. [3] Its main uses are in non-Hodgkin's lymphoma as part of the chemotherapy regimen CHOP R-CVP, Hodgkin's lymphoma as part of MOPP, COPP, BEACOPP, or the less popular Stanford V chemotherapy regimen in acute lymphoblastic leukemia (ALL), and in treatment for nephroblastoma as well as the ...
Injectable cladribine suppresses the body's ability to make new lymphocytes, natural killer cells, and neutrophils (called myelosuppression); data from hairy cell leukemia studies showed that about 70% of people taking the drug developed dangerously low levels of white blood cells and about 30% developed infections and some of those progressed ...